People: Talon Therapeutics Inc (TLON.OB)
TLON.OB on OTC BB
0.43USD
3:54pm EDT
0.43USD
3:54pm EDT
Price Change (% chg)
$-0.02 (-4.44%)
$-0.02 (-4.44%)
Prev Close
$0.45
$0.45
Open
$0.44
$0.44
Day's High
$0.45
$0.45
Day's Low
$0.42
$0.42
Volume
33,500
33,500
Avg. Vol
37,582
37,582
52-wk High
$1.83
$1.83
52-wk Low
$0.40
$0.40
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Leon Rosenberg |
80 | 2007 | Non-Executive Independent Chairman of the Board |
Steven Deitcher |
47 | 2007 | President, Chief Executive Officer, Director |
Craig Carlson |
64 | 2011 | Chief Financial Officer, Senior Vice President |
Samir Gharib |
29 | 2012 | Director - Finance, Controller |
Cecilia Gonzalo |
37 | 2011 | Director |
Howard Pien |
54 | 2012 | Director |
Elizabeth Weatherman |
53 | 2013 | Director |
Howard Furst |
46 | 2009 | Independent Director |
Paul Maier |
65 | 2008 | Independent Director |
Robert Spiegel |
62 | 2010 | Independent Director |
Biographies
| Name | Description |
|---|---|
Leon Rosenberg |
Dr. Leon E. Rosenberg, M.D., is Non-Executive Independent Chairman of the Board of Talon Therapeutics, Inc. Dr. Rosenberg has been a Professor in the Princeton University Department of Molecular Biology and the Woodrow Wilson School of Public and International Public Affairs since September 1997. Since July 1999, he has also been Professor Adjunct of Genetics at Yale University School of Medicine. From January 1997 to March 1998, Dr. Rosenberg served as Senior Vice President, Scientific Affairs of Bristol-Myers Squibb, and from September 1991 to January 1997, Dr. Rosenberg served as President of the Bristol-Myers Squibb Pharmaceutical Research Institute. From July 1984 to September 1991, Dr. Rosenberg was Dean of the Yale University School of Medicine. Dr. Rosenberg also serves on the Boards of Directors of Lovelace Respiratory Research Institute, Karo Bio AB, and Medicines for Malaria Venture. Dr. Rosenberg received B.A. and M.D. degrees, both summa cum laude, from the University of Wisconsin. He completed his internship and residency training in internal medicine at Columbia Presbyterian Medical Center in New York City. |
Steven Deitcher |
Dr. Steven R. Deitcher, M.D., is the President, Chief Executive Officer and a Director of Talon Therapeutics, Inc. He served as the company's Executive Vice President of Development and Chief Medical Officer from May 2007 to August 2007. Prior to joining Talon, Dr. Deitcher served as Vice President and Chief Medical Scientist at Nuvelo, Inc. since 2004. Prior to joining Nuvelo, from 1998 to 2004, Dr. Deitcher held a variety of positions in both the Department of Vascular Medicine and the Department of Hematology/Oncology while at The Cleveland Clinic Foundation, including Head of the Section of Hematology and Coagulation Medicine in the Department of Hematology/Oncology. Prior to that, he spent four years at The University of Tennessee in positions including Associate Chairman, Department of Medicine; Director, Combined Pediatric and Adult Thrombosis Clinic; and Director, Special Coagulation Laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. |
Craig Carlson |
Mr. Craig W. Carlson is Chief Financial Officer, Senior Vice President of Talon Therapeutics Inc. He joined Talon as Vice President on March 1, 2010, was appointed Chief Financial Officer effective April 1, 2010, and was promoted to Senior Vice President on December 16, 2010. Mr. Carlson has held senior leadership and executive financial management positions for the past 25 years, including positions at two public healthcare companies. Most recently, from February 2009 to February 2010, Mr. Carlson served as Chief Financial Officer and Chief Operating Officer for 20 Cent Ventures, a new business incubator focused primarily on applying life science technologies to high value niche opportunities worldwide, where he was responsible for managing several businesses, including four international subsidiaries. From July 2006 to March 2008, he was Chief Financial Officer of Neurobiological Technologies, Inc. and from 1993 to 2005 Mr. Carlson worked at Cygnus, Inc where he served as Chief Financial Officer and Chief Operating Officer. Mr. Carlson received his M.B.A. from the Stanford Graduate School of Business, his M.S. Ed. in Counseling from Hofstra University, and his B.A. in Political Science from Union College. |
Samir Gharib |
Mr. Samir M. Gharib, CPA, has been appointed as Director - Finance, Controller of Talon Therapeutics, Inc. He joined Talon as Controller, Director of Finance in January 2012. Prior to joining Talon as an employee, Mr. Gharib had served as Talon’s interim controller pursuant to the terms of an engagement agreement dated August 25, 2011 between Talon and Mr. Gharib’s former employer, CRC Results, Inc. (“CRC”), a consulting firm specializing in accounting, compliance, and risk advisory services. From January 2008 until January 6, 2012, Mr. Gharib provided accounting services to CRC’s public company clients in the financial services, technology, retail, healthcare, and real estate fields. Prior to joining CRC, Mr. Gharib was a member of KPMG’s Audit and Risk Advisory Services and Forensic Advisory Services groups from 2005 to 2007. Mr. Gharib earned a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley in May 2005. |
Cecilia Gonzalo |
Ms. Cecilia Gonzalo has been appointed as Director of Talon Therapeutics, Inc. She is a Managing Director at Warburg Pincus LLC and a General Partner of Warburg Pincus & Co., where she focuses on healthcare investments in the biotechnology, pharmaceuticals, and healthcare services sectors. Prior to joining Warburg Pincus in 2001, Ms. Gonzalo worked at Goldman Sachs in the firm’s Investment Banking Division focusing on corporate finance and mergers and acquisitions transactions in Latin America, as well as in the Principal Investment Area focusing on investments in the region. Ms. Gonzalo received a B.A., cum laude, in Biochemical Sciences from Harvard College and an M.B.A. from Harvard Business School. Ms. Gonzalo also serves as a director of Allos Therapeutics and Rib-X Pharmaceuticals. |
Howard Pien |
Mr. Howard H. Pien has been appointed as Director of Talon Therapeutics, Inc., effective April 20, 2012. He served as President and Chief Executive Officer of Medarex, Inc., a biotechnology company, from June 2007 until Medarex's acquisition by Bristol-Myers Squibb in September 2009. Prior to that, Mr. Pien served as the President and Chief Executive Officer and a director of Chiron Corporation from April 2003 until Chiron's acquisition by Novartis in April 2006. Mr. Pien joined Chiron from GlaxoSmithKline, where he had responsibility as President, Pharmaceuticals International from December 2000 to March 2003. Mr. Pien previously held key positions in SmithKline Beecham's pharmaceuticals business in North America, the United Kingdom, and North Asia, culminating in his tenure as President, Worldwide Pharmaceuticals. Prior to joining SmithKline Beecham, Mr. Pien worked for Abbott Laboratories for six years and for Merck & Co. for five years, in positions of sales, marketing research, licensing and product management. Mr. Pien currently serves as a director of ViroPharma Incorporated, Vanda Pharmaceuticals, Inc., and ImmunoGen, Inc., each a publicly-traded biotechnology company. He also serves as a director of Ikaria, a privately-held life sciences company, and as an advisor to Warburg Pincus, a private equity firm. Mr. Pien holds a B.S. degree from the Massachusetts Institute of Technology and an M.B.A. from Carnegie-Mellon University. |
Elizabeth Weatherman |
Ms. Elizabeth H. Weatherman is appointed as the Director of Talon Therapeutics, Inc. She is a General Partner of Warburg Pincus & Co., a Managing Director of Warburg Pincus LLC and a member of the firm's Executive Management Group. Ms. Weatherman joined Warburg Pincus in 1988 and is currently responsible for the firm's U.S. healthcare investment activities. Ms. Weatherman currently serves on the board of directors of Tornier, Inc., Bausch + Lomb Incorporated and several other privately held companies. During the past five years, Ms. Weatherman previously served on the board of directors of ev3 Inc. and Kyphon, Inc. Ms. Weatherman earned a Master of Business Administration from the Stanford Graduate School of Business and a Bachelor of Arts from Mount Holyoke College. |
Howard Furst |
Dr. Howard P. Furst, M.D., serves as Independent Director of Talon Therapeutics, Inc. Dr. Furst has over 20 years of experience in the healthcare industry and is currently a partner at Deerfield Management, a healthcare investment fund based in New York City, where he is primarily responsible for overseeing the firm’s private investments. Prior to joining Deerfield Management in 2007, Dr. Furst was a portfolio manager for the healthcare group at Magnetar Capital, an investment fund, from 2006 to 2007. Prior to joining Magnetar Capital, Dr. Furst was a principal at Maverick Capital, an investment firm, where he was primarily responsible for managing the firm’s investments in the pharmaceutical and biotechnology sectors. Dr. Furst received his M.D. from the New York University School of Medicine, an M.B.A. with a dual concentration in finance and healthcare administration from the Wharton School of Business at the University of Pennsylvania, and a B.A. from the University of Pennsylvania. Dr. Furst also serves as a director of the following privately-held companies: Eclat Pharmaceuticals, New American Therapeutics, and Veterinary Practice Partners. |
Paul Maier |
Mr. Paul V. Maier is Independent Director of Talon Therapeutics, Inc., since March 2008. Since November 2009, Mr. Maier has served as Chief Financial Officer of Sequenom, Inc., a publicly-held biotechnology company. From January 2007 until November 2009, he served as an independent financial consultant. From October 1992 to January 2007, Mr. Maier served as Senior Vice President, Chief Financial Officer of Ligand Pharmaceuticals, Inc., a publicly-held biopharmaceutical company based in San Diego, CA. Prior to joining Ligand, Mr. Maier served as Vice President, Finance at DFS West, a division of DFS Group, L.P., a private multinational retailer from October 1990 to October 1992. From February 1990 to October 1990, Mr. Maier served as Vice President and Treasurer of ICN Pharmaceuticals, Inc., a pharmaceutical and biotechnology research products company. Mr. Maier held various positions in finance and administration at SPI Pharmaceuticals, Inc., a publicly held subsidiary of ICN Pharmaceuticals Group, from 1984 to 1988, including Vice President, Finance from February 1984 to February 1987. Mr. Maier also serves on the boards of directors of Pure Bioscience, Inc. and International Stem Cell Corp., both publicly-held companies. Mr. Maier received an M.B.A. from Harvard Business School and a B.S. from Pennsylvania State University. |
Robert Spiegel |
Dr. Robert J. Spiegel, M.D., has been appointed as Independent Director of Talon Therapeutics, Inc., effective July 30, 2010 after being designated by Warburg Pincus pursuant to its rights under June 2010 Investment Agreement. From 1983 until his retirement in November 2009, Dr. Spiegel was employed by Schering Plough, serving in a number of positions of increasing responsibility, including Chief Medical Officer from 1998 until 2009. Prior to joining Schering Plough, Dr. Spiegel was an Assistant Professor, Department of Medicine, NYU Medical Center. Dr. Spiegel obtained his M.D. from the University of Pennsylvania and a B.A., cum laude, from Yale University. Dr. Spiegel also serves as a director of Geron Corporation and Clavis Pharma, both publicly-held biopharmaceutical companies. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Leon Rosenberg |
-- |
Steven Deitcher |
707,783 |
Craig Carlson |
446,147 |
Samir Gharib |
-- |
Cecilia Gonzalo |
-- |
Howard Pien |
-- |
Elizabeth Weatherman |
-- |
Howard Furst |
-- |
Paul Maier |
-- |
Robert Spiegel |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Leon Rosenberg |
0 | 0 |
Steven Deitcher |
0 | 0 |
Craig Carlson |
0 | 0 |
Samir Gharib |
0 | 0 |
Cecilia Gonzalo |
0 | 0 |
Howard Pien |
0 | 0 |
Elizabeth Weatherman |
0 | 0 |
Howard Furst |
0 | 0 |
Paul Maier |
0 | 0 |
Robert Spiegel |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
FLYNN JAMES E |
112,693 | $1.22 |
FLYNN JAMES E |
141,750 | $1.22 |
FLYNN JAMES E |
57,165 | $1.22 |
FLYNN JAMES E |
228,392 | $1.22 |
FLYNN JAMES E |
114,937 | $1.33 |
FLYNN JAMES E |
232,940 | $1.33 |
FLYNN JAMES E |
58,303 | $1.33 |
FLYNN JAMES E |
58,303 | $1.33 |
FLYNN JAMES E |
144,572 | $1.33 |
FLYNN JAMES E |
144,572 | $1.33 |
FLYNN JAMES E |
232,940 | $1.33 |
FLYNN JAMES E |
114,937 | $1.33 |
FLYNN JAMES E |
34,752 | $1.20 |
FLYNN JAMES E |
43,713 | $1.20 |
FLYNN JAMES E |
70,433 | $1.20 |
FLYNN JAMES E |
43,713 | $1.20 |
FLYNN JAMES E |
70,433 | $1.20 |
FLYNN JAMES E |
17,629 | $1.20 |
FLYNN JAMES E |
34,752 | $1.20 |
FLYNN JAMES E |
17,629 | $1.20 |
FLYNN JAMES E |
40,619 | $1.14 |
FLYNN JAMES E |
82,321 | $1.14 |
FLYNN JAMES E |
51,091 | $1.14 |
FLYNN JAMES E |
20,604 | $1.14 |
FLYNN JAMES E |
57,697 | $1.07 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
